RxDoctor Payments Data

Maria Diaz, MD

Internal Medicine · Bronx, NYNPI 1558451450

Payments from drug & device makers

$2,206in general payments, 2019–2025

Across 35 payments — averaging $63.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$918
  • E.r. Squibb & Sons, L.L.C.$227
  • Acadia Pharmaceuticals Inc$152
  • Kyowa Kirin, Inc.$150
  • Esperion Therapeutics, Inc.$148
  • Amgen$140
  • plus $470 from 5 others

What the payments were for

  • Speaking & faculty fees$251%
  • Food & beverage$2,18299%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,206 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$16,615
Medicare patients
54
Services billed
178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin431$341,279
OzempicSemaglutide340$314,522
JanuviaSitagliptin Phosphate267$225,249
TrulicityDulaglutide212$220,461
EliquisApixaban146$102,532
JanumetSitagliptin Phos/Metformin Hcl91$67,383
RybelsusSemaglutide48$51,584
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog164$50,921
LinzessLinaclotide87$49,616
EntrestoSacubitril/Valsartan46$43,313
Trelegy ElliptaFluticasone/Umeclidin/Vilanter59$39,261
FarxigaDapagliflozin Propanediol46$37,441
XifaxanRifaximin11$33,638
Diclofenac Sodium554$29,924
RestasisCyclosporine54$29,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$918$366,106388 claims
Boehringer IngelheimJardiance, Tradjenta$15$356,405456 claims
AbbVieLinzess, Restasis, Creon$125$85,304158 claims
GSKTrelegy Ellipta, Breo Ellipta$135$58,689108 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →